skip to main
|
skip to sidebar
Xcovery blog - kinase industry knowledge collected and sometimes analyzed
Thursday, October 12, 2006
PIramed-Genentech
Aggregate value of $230M; undisclosed upfront
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Kinase Industry Biz News
Links
Multi-targeted Therapy
All things chromatin
Guide to biotech IP
IHOP - great protein db
Kinase research portal
Seeking Alpha - solid biotech investment insight
Decent but dated summary of kinase therapeutics
Biotech licensing blog
Research VEGF
Therapeutic Angiogenesis
Xcovery
Email Tim (sitehost)
Blog Roll
KinasePro
Bio Health Investor
Biotechnology Stocks
In the pipeline
Omics! Omics!
On Bio VC
Org Prep Daily (home of Milkshake)
The Curious Waveform
Tim's Personal Blog
Totally Medicinal
Whistling in the Wind
Cool liks
Pfizer's RTK animation
ArQule's c-Met animation
Kinase efforts you may not know of
Calistoga Pharma (PI-3 p110 delta)
Semafore (PI3)
KAI Pharma (PKC-delta)
Locus (p38 & unnamed multi-TK)
Pharmacyclics (Btk)
Coratus
Tigris Pharmaceuticals
Blog Archive
►
2012
(1)
►
March
(1)
►
2007
(33)
►
March
(5)
►
February
(8)
►
January
(20)
▼
2006
(54)
►
December
(5)
►
November
(34)
▼
October
(15)
Array Pharma advances p38 lead to clinic
TAK1 - key activator of AMPK signaling?
VEGFR for non-cancer vascular applications?
Gleevec wins expanded approval
Average clinical trial costs
Another big TK inhibitor deal
Met TK linked to autism
treatment for EGFR skin rashes
Leonard Saltz on targeted therapies
CGI-Genentech
Roche-Plexxikon B-Raf deal
PIramed-Genentech
2010: kinases $58B annually (Pharmaprojects)
EGFR market....
Dual Drug Approach Gives Reason to Cheer
Google search
Web
xcovery.blogspot.com
Sitemeter
Technorati
clustermap
Cloud
Labels
2007
(1)
ABT-737
(1)
Accelrys
(1)
access
(1)
Akt
(2)
ALL
(2)
Alliances
(1)
Ambit
(1)
AMG 706
(2)
AMGN
(1)
AML
(1)
Amphora
(1)
Ariad
(1)
ARRY
(4)
ARRY-543
(1)
ARRY-797
(1)
Arxxant
(1)
Aurora
(2)
Avastin
(3)
Aveon
(1)
Axitinib
(1)
Axl
(1)
AZ
(1)
basics
(1)
Bayer
(2)
Bcr-abl
(1)
BI
(1)
BI-2536
(1)
BIBF-1120
(1)
BIBW-2992
(1)
Biomira
(1)
BMS
(4)
BREL
(1)
business models
(1)
cancer
(2)
CDK4
(2)
Celebrex
(1)
Cephalon
(1)
CGI
(1)
chemo
(1)
CML
(1)
CML NVS
(1)
cool
(2)
Cox-2
(1)
CP-690550
(1)
CP-751871
(1)
Curagen
(1)
CYC116
(1)
Cyclacel
(3)
discovery
(1)
DNA
(10)
EGFR
(3)
erb-b2
(2)
Exelixis
(2)
finance
(1)
Flt-3
(1)
Gleevec
(5)
GSK
(2)
HDI
(1)
herceptin
(2)
Icahn
(1)
IGFR-1
(1)
IKK
(1)
IMC-3G3
(1)
IMCL
(4)
inflammation
(1)
Innovive
(1)
IPO
(1)
Iressa
(1)
IVGN
(1)
JAK2
(1)
Jak3
(2)
Kit
(1)
Lilly
(1)
lung
(1)
M+ A
(1)
Market stats
(1)
MDACC
(1)
MEDI
(1)
Mek
(1)
Merck
(1)
Merrimack
(1)
Met
(2)
MK-0457
(1)
mutations
(1)
new targets
(2)
Nexavar
(5)
NVS
(3)
ONXX
(5)
OSIP
(3)
OSU-03012
(1)
P3
(1)
p38
(4)
Pathways
(1)
PCOP
(1)
PDGFR
(2)
pertuzumab
(2)
PFE
(3)
PI3
(3)
Pim
(1)
PKC
(1)
Plk
(1)
ProIX
(1)
prostate
(1)
RA
(3)
RCC
(3)
Sanofi
(1)
Scios
(1)
SGX
(3)
SGX-523
(2)
SNS-032
(1)
Sprycel
(1)
Src
(1)
Sunesis
(1)
SUPG
(1)
Sutent
(5)
TAK1
(1)
Tarceva
(3)
Targegen
(1)
Targeted therapies
(1)
Tasigna
(1)
thyroid
(1)
Torisel
(1)
trials
(1)
Tykerb
(3)
VEGF
(2)
VEGFR
(1)
VRTX
(1)
VX-680
(1)
WYE
(1)
Wyeth
(1)
Xcovery
(1)
XL518
(1)
XL999
(1)
Feeds
No comments:
Post a Comment